Serum Amyloid P-Component Prevents Cardiac Remodeling in ...

3 downloads 59 Views 4MB Size Report
Our results indicate that SAP prevents cardiac remodeling by inhibiting recruitment of pro-fibrotic macrophages and that depleted SAP levels identify patients ...
J. of Cardiovasc. Trans. Res. (2015) 8:554–566 DOI 10.1007/s12265-015-9661-1

Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease Stephen J. Horgan 1,2 & Chris J. Watson 1,2 & Nadia Glezeva 1,2 & Pat Collier 1,2,3 & Roisin Neary 1 & Isaac J. Tea 1 & Niamh Corrigan 1 & Mark Ledwidge 1,2 & Ken McDonald 1,2 & John A. Baugh 1

Received: 18 August 2015 / Accepted: 9 November 2015 / Published online: 17 November 2015 # Springer Science+Business Media New York 2015

Abstract The potential for serum amyloid P-component (SAP) to prevent cardiac remodeling and identify worsening diastolic dysfunction (DD) was investigated. The anti-fibrotic potential of SAP was tested in an animal model of hypertensive heart disease (spontaneously hypertensive rats treated with SAP [SHR−SAP]×12 weeks). Biomarker analysis included a prospective study of 60 patients with asymptomatic progressive DD. Compared with vehicle-treated Wistar-Kyoto rats (WKY-V), the vehicle-treated SHRs (SHR-V) exhibited significant increases in left ventricular mass, perivascular collagen, cardiomyocyte size, and macrophage infiltration. SAP administration was associated with significantly lower left ventricular mass (p